Stinger RF Cardiac Ablation Catheter Is Bard's First Entry Into $70 Mil. Market
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of C.R. Bard's Stinger radio frequency (RF) ablation catheter provides the company an entry into a growing $70 mil. U.S. therapeutic electrophysiology market.